Treatment with AS101 sensitizes acute myeloid leukemia cells (AML) to chemotherapy by disrupting the interaction between the integrin VLA-4 and Fibronectin: Mechanisms of action and clinical applications
acquired drug resistance - this is induced by the attachment of the integrin receptor VLA-4 on leukemic cells to its ligand fibronectin (FN) on bone marrow stromal cells. We show

